RDY Earnings

RDY reported its FY2025Q1 earnings on 2024-07-27, showcasing a revenue of 76.73B against an estimate of 72.71B, resulting in a 5.52% surprise. The EPS was 1, surpassing the expected 1.1 by -9.09%. The stock experienced a 0.47% price change on the earnings day and a 5.16% change over the next five days, reflecting market reactions to the results.

Following RDY's FY2025Q1 earnings announcement on 2024-07-27, the stock price moved by 0.47% on the day of the release. Over the subsequent five days, it saw a 5.16% change. Historically, RDY's stock price tends to shift by an average of 0.78% in the 10 days leading up to earnings and 1.18% in the 10 days following, providing insight into potential market.

For 2026/Q4, analysts estimate RDY's annual revenue to reach 85.08B, while the EPS is projected at 18.23. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between RDY's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RDY's stock price typically moves by 0.78% in the 10 days before its earnings and 1.18% in the 10 days after. For the upcoming 2026/Q4 earnings, analysts expect an EPS of 18.23 and revenue of 85.08B.

The earnings call summary and Q&A session reveal strong financial performance, product development, and market expansion strategies. Despite some challenges, such as lower gross margins and the wind-down of CAR-T investments, the company's optimistic guidance, new product launches, and market share gains indicate positive sentiment. The focus on emerging markets and sustainability goals further supports a positive outlook. The Q&A insights align with the earnings call, reinforcing the positive sentiment, especially with the expected growth in biosimilars and semaglutide. Therefore, the stock price is likely to experience a positive movement of 2% to 8%.